
News|Articles|October 1, 2011
FDA Pipeline Preview, October 2011 (Janssen Biotech, GlaxoSmithKline, Pfizer, Johnson & Johnson, Bayer AG, ApoPharma, BTG, Chelsea Therapeutics, QLT, Neuraltus Pharmaceuticals, Accentia, 4SC, Tarix Pharmaceuticals)
Recent FDA action (through September 2011) related to golimumab expanded label, meningococcal and Hib combination vaccine, desvenlafaxine, rivaroxaban anticoagulant, deferiprone oral iron chelator, glucarpidase experimental treatment, doxidopa, QLT091001, NP-001, cyclophosphamide, resminostat oral pan HDAC inhibitor, TXA127
Advertisement
Complete response
Recommendations for approval
Fast-track designations
Orphan drug designations
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Addressing Complex Dermatologic Conditions in Children | Fall Clinical Derm 2025
2
Atopic Dermatitis Treatment in Infants Should Not Wait | Fall Clinical Derm 2025
3
Dermatologist James Song Talks about Managing Psoriasis with IL-23 Inhibitors | Fall Clinical Derm 2025
4
Shawn Kwatra, M.D. Highlights Challenges in Treating Complex Skin Conditions | Fall Clinical Derm 2025
5
















































